A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Overview of attention for article published in Clinical Cancer Research, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

So far, Altmetric has seen 54 tweets from 34 users, with an upper bound of 52,917 followers.

RT @bvantine1: The latest work by @immunosarc is out in @CCR_AACR!! Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposa…

RT @bvantine1: The latest work by @immunosarc is out in @CCR_AACR!! Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposa…

El Ensayo de Fase I-II Que Combina #BABENCIO ( #AVELUMAB DE #MERCK / #PFIZER ) y #YONDELIS ( #TRABECTEDIN DE #PHARMAMAR ) Para el #LipoSarcoma Avanzado y el #Leiomiosarcoma ... No ha Alcanzado el Objetivo Principal de Respuesta Objetiva . https://t.co/CP0

RT @bvantine1: The latest work by @immunosarc is out in @CCR_AACR!! Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposa…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 50 additional tweets.